3029 Methyprylon Methyprylon is a sedative of the piperidinedione derivative family. This medicine was used for treating insomnia, but is now rarely used as it has been replaced by newer drugs with less side effects, such as benzodiazepines. Methyprylon was withdrawn from the US market in June 1965 and the Canadian market in September 1990. [Wikipedia] 125-64-4 4162 C10H17NO2 183.125930 White powder. 1.15E+004 mg/L Methyprylon binds at a distinct binding site associated with a Cl^- ionopore at the GABA_A receptor, increasing the duration of time for which the Cl^- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged. Hepatic. Methyprylon is almost completely metabolized. Half Life: 6-16 hours No indication of carcinogenicity to humans (not listed by IARC). For the treatment of insomnia. They cause slurred speech, disorientation and "drunken" behavior. They are physically and psychologically addictive. Symptoms of overdose include excitation and convulsions. 2009-07-21T20:28:23Z 2026-03-26T23:50:26Z Methyprylon 774741 Methyprylon DB01107 true CCC1(CC)C(=O)NCC(C)C1=O C10H17NO2 InChI=1S/C10H17NO2/c1-4-10(5-2)8(12)7(3)6-11-9(10)13/h7H,4-6H2,1-3H3,(H,11,13) SIDLZWOQUZRBRU-UHFFFAOYSA-N 183.2475 183.125928793 Exogenous Solid 0.78 HMDB15239 CHEMBL1200790 4018 CHEM002348 DTXSID7023306 NS00005672 3,3-diethyl-5-methylpiperidine-2,4-dione